# First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Source: https://onco.cc/trials/nct07529717/  
OnCo record `nct07529717` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD8359 in prostate cancer, run by AstraZeneca, now recruiting.

## Summary

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer is a phase 1/2 interventional study registered as NCT07529717 by AstraZeneca, with 42 participants planned, started 2026-05-18 and due to reach its primary completion in 2027-11-17. Interventions recorded: AZD8359.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07529717
- Phase: 1/2
- Setting: Phase I/II Dose Escalation & Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-guided T Cell-engaging Antibody That Targets STEAP2, in Adult Participants With Prostate Cancer
- Sponsor: AstraZeneca
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07529717: https://clinicaltrials.gov/study/NCT07529717

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07529717.json